I would like to thank the leader and Chairman Goodlatte for bringing H.R. 427 to the floor today. I introduced the REINS Act because people in my home State of Indiana want to hold someone--someone--accountable for the job-killing rules and regulations coming out of Washington, D.C. Each day, government agencies impose an average of 10 new regulations on America's businesses, both big and small. It is no surprise to discover that the costly, confusing government regulations that come out of this body--ObamaCare mandates, EPA regulations, or IRS tax penalties--are exciting some feedback from my constituents. In fact, the collateral damage wrought by Federal Government regulations is consistently cited as one of the biggest barriers to business creation and expansion and growth in household income in this country. One Indiana businessowner, who employs 16 family men and women in Floyd County, recently called my office. He wanted to know who had voted in support of a peculiar new IRS rule that is going to penalize him if he helps his employees pay for health insurance. Now, this IRS rule can cost employers more than $36,000 per employee per year if they continue to offend the sensibilities of Washington's regulating class by reimbursing workers for healthcare coverage.…
Todd Young: “I would like to thank the leader and Chairman Goodlatte for bringing H.R. 427 to the floor today. I introduced the REINS…”
On the recordJuly 28, 2015
Share
More from Todd Young
Aug 8, 2026
Russia’s aggression cannot continue without consequences, and those helping sustain Putin’s war machine should face meaningful costs.
Aug 10, 2026
Russia’s aggression cannot continue without consequences, and those helping sustain Putin’s war machine should face meaningful costs. This legislation gives the United States stronger leverage against Russia and those enabling its war. At…
Aug 27, 2026
This federal assistance is much needed and will strengthen ongoing local and state efforts.
Aug 5, 2026
If we cede global biotechnology leadership to China, we risk a future where high-skilled biotech jobs migrate abroad, first-in-class therapies do not reach American patients first, and pharmaceutical supply chains are strategically…





